MEDIPOST (078160) Fundamentals 2026 — Revenue Analysis | SniperIQ
MEDIPOST (078160) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩313.9B, trading at ₩8030.00 on the KOE. This SniperIQ fundamentals page covers MEDIPOST's valuation, profitability (net margin -107.7%), revenue (₩73.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MEDIPOST's market cap?
MEDIPOST (078160) has a market capitalization of approximately ₩313.9B, trading at ₩8030.00 on the KOE. Market cap moves with the live share price.
What is MEDIPOST's P/E ratio?
MEDIPOST's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MEDIPOST?
MEDIPOST runs a net profit margin of -107.7%, a gross margin of 62.4%, and an operating margin of -55.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MEDIPOST generate?
MEDIPOST reported revenue of ₩73.7B for fiscal year 2025, with net income of -₩85.4B and earnings per share (EPS) of -2193.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MEDIPOST pay a dividend?
MEDIPOST does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MEDIPOST financially healthy?
MEDIPOST carries a debt-to-equity ratio of 0.64x and a current ratio of 1.08x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MEDIPOST a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MEDIPOST (078160) the key facts are: market cap ₩313.9B, revenue ₩73.7B, 52-week range 7960-29100. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MEDIPOST's full fundamentals live
Get MEDIPOST's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.